Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2022-02-12 Legal Proceedings Report
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science - Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)
Legal Proceedings Report Classification · 1% confidence The document is a press release from AB Science dated February 12, 2022, providing clarifications following a public hearing of the Enforcement Committee of the French market regulator (AMF) regarding an investigation into financial information and insider trading allegations. It details the ongoing legal/regulatory process, including the Rapporteur's independent report and the expected decision timeline. This content directly relates to significant legal proceedings and regulatory actions involving the company. Therefore, it fits the definition of a Legal Proceedings Report (LTR). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it specifically addresses a legal/enforcement matter.
2022-02-12 English
AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit
Regulatory Filings Classification · 1% confidence The document is a press release dated February 7, 2022, announcing that AB Science will present data on its ALS development program at an upcoming industry summit (ALS Drug Development Summit in May 2022). It details the presentation topic, quotes a key executive, and provides background on the drug masitinib and related clinical trials (AB10015 and AB19001). This type of announcement, which communicates an upcoming event where company information will be shared, is best classified as a general corporate announcement or regulatory filing that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is an announcement about future corporate activity and data presentation, and it is not a formal financial report, a proxy statement, or a management discussion, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for corporate news releases that don't fit elsewhere, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the nature of the content (a press release about an upcoming presentation at a conference), RNS is the most suitable fallback, although it shares characteristics with an Investor Presentation announcement. However, since it is a press release format announcing participation in an external event, RNS is the standard classification for such corporate news.
2022-02-07 English
AB Science présentera son programme de développement dans la Sclérose Latérale Amyotrophique (SLA) lors de l’édition 2022 du ALS Drug Development Summit
Regulatory Filings Classification · 1% confidence The document is a press release dated February 7, 2022, announcing that AB Science will present its development program for Masitinib in Amyotrophic Lateral Sclerosis (ALS) at the 2022 ALS Drug Development Summit. It details the presentation topic, quotes the Scientific Committee President, provides background on ongoing clinical trials (AB10015 and AB19001), and includes standard company information and forward-looking statements. This type of announcement, focusing on participation in an industry event or conference presentation, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it contained financial results. Since this is an announcement about presenting clinical development data at a summit, and it is not a formal regulatory filing (like 10-K or IR), nor a transcript (CT), nor a formal earnings release (ER), it best fits the category for detailed investor-focused material, which is Investor Presentation (IP), or potentially a general Regulatory Filing (RNS) if the focus was purely administrative. However, given the detailed discussion of clinical trial results and development strategy aimed at investors and key opinion leaders, 'Investor Presentation' (IP) is the most appropriate fit, as it communicates strategic and clinical updates often found in investor presentations, even if this specific document is the announcement of the presentation itself. Since it is an announcement *about* presenting data, and not the presentation document itself, it could also be argued as a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Given the content is substantive clinical/development news, and not just 'the report is attached', I will lean towards IP as the intended information category, but acknowledge the ambiguity. If the document was purely announcing the *release* of a report, RPA would be better. Since it announces a *presentation* of data, IP is stronger than RNS/RPA.
2022-02-07 French
AB Science a reçu l’autorisation de l’Agence de Santé Suédoise pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received authorization from the Swedish Health Agency to initiate a Phase III confirmatory study for Masitinib in progressive forms of Multiple Sclerosis. It details the study title, references previous positive Phase 2B/3 results, and provides background on the disease and the company. This type of announcement, detailing clinical trial progress and regulatory milestones, is characteristic of an Earnings Release (ER) if it were focused purely on financial results, or a general Regulatory Filing (RNS). However, since it is a specific announcement about clinical trial progress and regulatory clearance for a drug study, it is best classified as a general announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Given the options, and since it is a press release detailing a significant operational/regulatory event (clinical trial authorization), it falls under the broad category of Regulatory Filings (RNS) or potentially an Earnings Release (ER) if such announcements are grouped there, but RNS is the most appropriate fallback for non-standard, non-financial-statement regulatory news. Since it is a press release announcing a regulatory/clinical event, and not a formal financial report, RNS is the best fit among the provided codes, acting as a general regulatory announcement category.
2022-02-02 French
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that AB Science has received authorization from the Swedish Medical Products Agency to initiate a confirmatory Phase III trial for masitinib in Multiple Sclerosis. This is a time-sensitive announcement regarding clinical trial progress and regulatory milestones, typical of corporate news releases. It is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a presentation (IP). Since it is a general, time-sensitive corporate announcement that doesn't fit the highly specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), it falls best under the general Regulatory Filings/Announcements category, RNS, as it reports on regulatory interaction and trial initiation. Given the nature of the announcement (regulatory authorization for a clinical trial), RNS is the most appropriate general classification.
2022-02-02 English
AB Science a reçu l’autorisation de l’ANSM pour initier une étude de Phase II chez les patients atteints du syndrome d’activation des mastocytes sévère
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received authorization from the ANSM (French regulatory authority) to initiate a Phase II clinical study (AB20006) for treating severe Mast Cell Activation Syndrome (MCAS). This content details regulatory/clinical trial progress and is a formal announcement to the public and investors, rather than a comprehensive financial report (like 10-K or IR) or a transcript. It is a specific type of corporate announcement. Since it is not a standard financial report, a management change, a dividend notice, or a proxy statement, it falls best under the category of general regulatory/corporate news. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news that isn't explicitly covered by other codes, although it strongly relates to clinical trial progress. However, since the core subject is the initiation of a clinical trial following regulatory approval, and it is presented as a press release, it is a general corporate announcement. If a more specific 'Clinical Trial Update' existed, that would be preferred. In the absence of such a code, RNS (Regulatory Filings/General Announcement) is the best fit for this type of press release detailing regulatory/clinical milestones.
2022-01-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.